Literature DB >> 21722328

Identification of DNA repair gene Ercc1 as a novel target in melanoma.

Liang Song1, Ann-Marie Ritchie, Ewan M McNeil, Weiling Li, David W Melton.   

Abstract

Increased expression of DNA repair genes contributes to the extreme resistance shown by melanoma to conventional DNA-damaging chemotherapeutics. One such chemotherapeutic effective against a range of other cancers, but not melanoma, is cisplatin. The DNA repair protein, ERCC1, is needed to remove cisplatin-induced DNA damage. We have shown that ERCC1 is essential for melanoma growth and resistance to cisplatin in a mouse xenograft model. Untreated xenografts of our transformed Ercc1-proficient melanocyte cell line grew very rapidly as malignant melanoma. Cisplatin treatment caused initial shrinkage of xenografts, but cisplatin-resistant regrowth soon followed. Cells reisolated into culture had twofold elevated levels of ERCC1 compared to both input cells and cells reisolated from untreated xenografts. An isogenic Ercc1-deficient derivative grew equally well in vitro as the Ercc1-proficient melanocyte cell line. However, in xenografts, the Ercc1-deficient melanomas were much slower to establish and were completely cured by just two cisplatin treatments.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21722328     DOI: 10.1111/j.1755-148X.2011.00882.x

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN: 1755-1471            Impact factor:   4.693


  11 in total

1.  Melanoma cells replicate through chemotherapy by reducing levels of key homologous recombination protein RAD51 and increasing expression of translesion synthesis DNA polymerase ζ.

Authors:  Liang Song; Ewan M McNeil; Ann-Marie Ritchie; Katy R Astell; Charlie Gourley; David W Melton
Journal:  BMC Cancer       Date:  2017-12-18       Impact factor: 4.430

2.  ERCC1 Is a Predictor of Anthracycline Resistance and Taxane Sensitivity in Early Stage or Locally Advanced Breast Cancers.

Authors:  Tarek M A Abdel-Fatah; Reem Ali; Maaz Sadiq; Paul M Moseley; Katia A Mesquita; Graham Ball; Andrew R Green; Emad A Rakha; Stephen Y T Chan; Srinivasan Madhusudan
Journal:  Cancers (Basel)       Date:  2019-08-10       Impact factor: 6.639

3.  The effects of ERCC1 expression levels on the chemosensitivity of gastric cancer cells to platinum agents and survival in gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy.

Authors:  Yong-Ping Liu; Yang Ling; Qiu-Feng Qi; Ya-Ping Zhang; Chang-Song Zhang; Chang-Tai Zhu; Mei-Hua Wang; Yao-Dong Pan
Journal:  Oncol Lett       Date:  2012-12-28       Impact factor: 2.967

Review 4.  The role of altered nucleotide excision repair and UVB-induced DNA damage in melanomagenesis.

Authors:  Timothy Budden; Nikola A Bowden
Journal:  Int J Mol Sci       Date:  2013-01-09       Impact factor: 5.923

Review 5.  DNA repair endonuclease ERCC1-XPF as a novel therapeutic target to overcome chemoresistance in cancer therapy.

Authors:  Ewan M McNeil; David W Melton
Journal:  Nucleic Acids Res       Date:  2012-08-31       Impact factor: 16.971

6.  Sequential decitabine and carboplatin treatment increases the DNA repair protein XPC, increases apoptosis and decreases proliferation in melanoma.

Authors:  Timothy Budden; Andre van der Westhuizen; Nikola A Bowden
Journal:  BMC Cancer       Date:  2018-01-26       Impact factor: 4.430

7.  Identification of small molecule inhibitors of ERCC1-XPF that inhibit DNA repair and potentiate cisplatin efficacy in cancer cells.

Authors:  Sanjeevani Arora; Joshua Heyza; Hao Zhang; Vivian Kalman-Maltese; Kristin Tillison; Ashley M Floyd; Elaine M Chalfin; Gerold Bepler; Steve M Patrick
Journal:  Oncotarget       Date:  2016-11-15

8.  Disruption of DNA repair in cancer cells by ubiquitination of a destabilising dimerization domain of nucleotide excision repair protein ERCC1.

Authors:  Lanlan Yang; Ann-Marie Ritchie; David W Melton
Journal:  Oncotarget       Date:  2017-07-21

9.  Excision repair cross-complementing group 1 (ERCC1) overexpression inhibits cell apoptosis and is associated with unfavorable prognosis of esophageal squamous cell carcinoma.

Authors:  Haiying Peng; Shaobo Yao; Qingyu Dong; Yanxia Zhang; Weihong Gong; Zhongyao Jia; Li Yan
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817

10.  Melanoma cells resistant towards MAPK inhibitors exhibit reduced TAp73 expression mediating enhanced sensitivity to platinum-based drugs.

Authors:  Elena Makino; Vanessa Gutmann; Corinna Kosnopfel; Heike Niessner; Andrea Forschner; Claus Garbe; Tobias Sinnberg; Birgit Schittek
Journal:  Cell Death Dis       Date:  2018-09-11       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.